D. Boral Capital Reaffirms Buy Rating for Can-Fite BioPharma (NYSE:CANF)

Can-Fite BioPharma (NYSE:CANF)‘s stock had its “buy” rating reiterated by analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the stock.

Separately, StockNews.com began coverage on Can-Fite BioPharma in a research report on Saturday, March 15th. They issued a “sell” rating for the company.

Can-Fite BioPharma Trading Down 19.4 %

Shares of Can-Fite BioPharma stock opened at $1.63 on Tuesday. The firm has a market capitalization of $5.77 million, a P/E ratio of -0.91 and a beta of 1.12. The business’s fifty day simple moving average is $1.59 and its 200 day simple moving average is $1.88. Can-Fite BioPharma has a 12 month low of $1.29 and a 12 month high of $4.69.

Institutional Trading of Can-Fite BioPharma

An institutional investor recently raised its position in Can-Fite BioPharma stock. Rhumbline Advisers raised its stake in Can-Fite BioPharma Ltd. (NYSE:CANF) by 58.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,880 shares of the company’s stock after buying an additional 9,935 shares during the period. Rhumbline Advisers owned about 0.76% of Can-Fite BioPharma worth $44,000 at the end of the most recent quarter. 21.00% of the stock is currently owned by hedge funds and other institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.